ELITE PHARMACEUTICALS INC NV (ELTP)
2025-06-30 | 2024-12-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 40,211,097 | 14,364,248 | 18,880,345 | 18,803,063 |
| Cost of manufacturing | 12,985,127 | 8,244,907 | 10,682,917 | 10,328,285 |
| Gross profit | 27,225,970 | 6,119,341 | 8,197,428 | 8,474,778 |
| Research and development | 1,674,964 | 1,793,803 | 1,966,094 | 2,163,527 |
| General and administrative | 3,404,084 | 2,724,616 | 2,273,744 | 1,969,154 |
| Depreciation and amortization | 394,886 | 432,534 | 420,318 | 425,712 |
| Non-cash compensation through issuance of stock options | 52,329 | 70,578 | 52,329 | 52,329 |
| Total operating expenses | 5,526,263 | 5,021,531 | 4,712,485 | 4,610,722 |
| Income from operations | 21,699,707 | 1,097,810 | 3,484,943 | 3,864,056 |
| Other income | - | 51,308 | - | 12,000 |
| Interest income | 4,542 | 5,092 | 5,902 | 5,390 |
| Change in fair value of derivative financial instruments - warrants | -22,109,537 | -11,729,368 | -12,754,735 | -2,782,913 |
| Interest expense and amortization of debt issuance costs | 158,926 | 77,607 | 255,136 | 250,781 |
| Other expense, net | -22,263,921 | -11,750,575 | -13,003,969 | -3,016,304 |
| (loss) income before income taxes | -564,214 | -10,652,765 | -9,519,026 | 847,752 |
| Income tax expense | 5,320,501 | 239,175 | 1,517,203 | 231,979 |
| Net (loss) income | -5,884,715 | -10,891,940 | -11,036,229 | 615,773 |
| Basic net (loss) income per share attributable to common shareholders | -0.01 | -0.01 | -0.01 | - |
| Basic weighted average common stock outstanding | 1,068,363,108 | 1,068,273,108 | 1,068,273,108 | 1,068,273,108 |
| Diluted net (loss) income per share attributable to common shareholders | -0.01 | -0.01 | -0.01 | - |
| Diluted weighted average common stock outstanding | 1,068,363,108 | 1,068,273,108 | 1,068,273,108 | 1,076,250,204 |